News/Events/Local Blog

A new study found that non-Hispanic Black individuals with systemic lupus erythematosus (SLE) experienced the highest rates of maternal cardiovascular events, maternal adverse pregnancy outcomes and infant adverse outcomes.Read more

A new investigative therapy, afimetoran, for adults with systemic lupus erythematosus (SLE) met its primary endpoint in a Phase 2 global, double-blind, randomized, dose-ranging, placebo-controlled trial (NCT04895696), showing a clear, statistically significant, and clinically meaningful benefit. Afimetoran is a selective, oral, once-daily...Read more

A new study comparing perspectives about disease flares in people with systemic autoimmune rheumatic diseases (SARD), like systemic lupus erythematosus (SLE), and clinicians found differences in how each recognizes a flare, especially in how quickly they begin and how they are identified.Read more

A new study found two distinct biological patterns of lupus nephritis (LN), offering researchers a closer look at why kidney involvement may vary from person to person.Read more

A new study suggests that people with systemic lupus erythematosus (SLE) who have inadequate exposure to hydroxychloroquine (HCQ) may have higher estimated atherosclerotic cardiovascular (ASCVD) disease risk.Read more

A new study identified 39 candidate measures for an updated tool to better assess long-term organ damage in people with systemic lupus erythematosus (SLE).Read more

A new study of adults with systemic lupus erythematosus (SLE) found cerebral atrophy or brain shrinkage is linked to older age, longer disease duration, lower education levels, presence of neuropsychiatric systemic lupus erythematosus (NPSLE), and more severe disease damage and cognitive difficultiesRead more

A new study found that higher glucocorticoid (steroid) exposure and limited practical social support were associated with an increased risk of long-term neuropsychiatric damage in people with systemic lupus erythematosus (SLE).Read more